Published: Sat, January 13, 2018
Worldwide | By Isabel Fisher

Seattle Genetics (SGEN) Given a $50.00 Price Target at Cantor Fitzgerald

About 502,450 shares traded.

From another technical standpoint, Seattle Genetics, Inc. It has outperformed by 58.98% the S&P500. SWN's SI was 44.85M shares in January as released by FINRA. Its revenue totaled $112.8 million up 4.23% from the previous quarter. With 13.06M avg volume, 3 days are for Southwestern Energy Company (NYSE:SWN)'s short sellers to cover SWN's short positions. Century Companies stated it has 9,816 shares or 0% of all its holdings. The stock increased 1.93% or $0.31 during the last trading session, reaching $16.4. Another trade for 6,000 shares valued at $201,000 was made by DREISMANN HEINRICH on Monday, December 11. MEDNAX, Inc. (NYSE:MD) has declined 18.20% since January 12, 2017 and is downtrending.

Seattle Genetics earned a daily sentiment score of 0.20 on Accern's scale. Its down 0.52, from 1.3 in 2017Q2. It dropped, as 51 investors sold SGEN shares while 74 reduced holdings. 29 funds opened positions while 69 raised stakes.

The counter witnessed a trading volume of 2.97 million shares versus an average volume of 5.06 million shares during last trading session. Pictet Asset Mngmt Ltd has invested 0.2% in Seattle Genetics, Inc. The share last price represents downtick move of -25.15% in value from company's 52-Week high price and shows 17.81% above change in value from its 52-Week low price. State Street Corporation owns 3.23M shares or 0.02% of their USA portfolio. Rmb Cap Ltd Liability Corp reported 53,145 shares. Jfs Wealth Limited Liability Company invested in 275 shares or 0% of the stock. Bourgeon Cap Mgmt Ltd Limited Liability Company has invested 0.03% of its portfolio in Regulus Therapeutics Inc. Peak6 Lp holds 0% of its portfolio in Seattle Genetics, Inc.

SGEN has been the topic of a number of recent research reports. (NASDAQ:MYGN). Virginia Retirement System Et Al reported 48,500 shares stake. Moreover, Manufacturers Life Insur The has 0% invested in Seattle Genetics, Inc. Ascend Cap Limited Liability Company invested in 164,648 shares or 0.34% of the stock. 125,000 are held by Rock Springs Cap L P. Spark Invest Management Lc accumulated 0.54% or 183,500 shares.

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. Alliancebernstein Ltd Partnership holds 0% in Myriad Genetics, Inc. ADVISORS LP with 45.73 million shares, BAILLIE GIFFORD & CO with 15.41 million shares, PRIMECAP MANAGEMENT CO/CA/ with 12.78 million shares, VANGUARD GROUP INC with 7.67 million shares, and BLACKROCK INC. with 7.54 million shares. State Common Retirement Fund owns 265,358 shares for 0.02% of their portfolio. Walleye Trading Ltd has 25,983 shares for 0% of their portfolio. Seattle Genetics, Inc. (NASDAQ:SGEN) has risen 75.68% since January 13, 2017 and is uptrending. Therefore 39% are positive. Also, the current price highlights a discount of 60.49% to analysts' high consensus price target. Oppenheimer initiated Seattle Genetics, Inc. (NASDAQ:MYGN) rating on Monday, June 12. As per Thursday, April 13, the company rating was maintained by BMO Capital Markets. On Monday, June 26 the stock rating was maintained by Cowen & Co with "Hold". The stock has "Buy" rating by Gabelli on Wednesday, August 9. (NASDAQ:SGEN) rating on Monday, June 26. The firm has "Hold" rating given on Tuesday, August 29 by Cantor Fitzgerald. Guggenheim restated a buy rating and set a $72.00 target price on shares of Seattle Genetics in a research note on Monday, October 23rd. The stock has "Outperform" rating by RBC Capital Markets on Monday, October 10. (NASDAQ:SGEN) on Friday, September 15 with "Buy" rating.

Since August 7, 2017, it had 0 buys, and 17 selling transactions for $9.99 million activity. Shares for $501,176 were sold by SIMPSON TODD E on Wednesday, September 6. Also, EVP Darren S. Cline sold 10,000 shares of the business's stock in a transaction dated Tuesday, December 13th. SIEGALL CLAY B sold $509,300 worth of stock. Over the last five days, shares have faced -6.75% losses and now is down -10.34% since hitting its 200-day moving average of $54.78. DRACHMAN JONATHAN G sold 8,502 shares worth $407,199. The stock was sold at an average price of $60.91, for a total value of $2,398,940.35. Cutera had 8 analyst reports since January 4, 2017 according to SRatingsIntel. During the same period previous year, the firm earned ($0.23) EPS. Oppenheimer reissued a "hold" rating on shares of Seattle Genetics in a research note on Tuesday, January 2nd. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. Therefore 28% are positive. TheStreet upgraded Seattle Genetics from a "d" rating to a "c" rating in a report on Thursday, November 16th. The company was maintained on Wednesday, August 16 by Oppenheimer. (NASDAQ:SGEN) earned "Hold" rating by Cowen & Co on Tuesday, June 6. Chardan Capital Markets maintained Regulus Therapeutics Inc. The stock of Southwestern Energy Company (NYSE:SWN) has "Hold" rating given on Sunday, August 16 by Zacks. Chardan Capital Markets has "Buy" rating and $500 target. The firm earned "Buy" rating on Wednesday, December 7 by Chardan Capital Markets.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Like this: